Author

Lauren E. Sedita

Observed names: L Sedita, L. Sedita, Lauren E Sedita, Lauren Sedita, Sedita, Lauren E.

Institution: Sarepta Therapeutics (United States)

Observed institution: Sarepta Therapeutics (United States)

ORCID: 0000-0003-0899-1585

Observed ORCID: 0000-0003-0899-1585

OpenAlex ID: A5032826017

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States

2023 · Alexa C. Klimchak, Lauren E. Sedita, et al. · Journal of Market Access & Health Policy · 16

Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec

2023 · Damon Asher, Daisy Dai, et al. · Molecular Therapy — Methods & Clinical Development · 11

Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies

2020 · Irfan Khan, Eric D. Peterson, et al. · Journal of the American Heart Association · 10

Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study

2024 · Alexa C. Klimchak, Lauren E. Sedita, et al. · Value in Health · 6

P1 Quantifying the Insurance and Altruism Value for Rare Diseases: A Case Study for Duchenne Muscular Dystrophy

2023 · J. Shafrin, S. Thahir, et al. · Value in Health · 5

Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs

2023 · Nola B Jenkins, Julia A Rucker, et al. · Journal of Managed Care & Specialty Pharmacy · 3

Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions

2024 · Lauren A. Do, Lauren E. Sedita, et al. · Health and Quality of Life Outcomes · 2

The Paradox of Life Extension with Traditional Cost-Effectiveness Analysis: A Case Study with Duchenne Muscular Dystrophy

2026 · Lauren Sedita, Alexa Klimchak, et al. · Journal of health economics and outcomes research · 1

Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United States

2025 · Jason Shafrin, Nadine Zawadzki, et al. · Current Medical Research and Opinion · 1

Assessing the impact of single or short-term administration on a therapy’s cost-effectiveness: a hypothetical disease-agnostic model

2023 · Alexa C. Klimchak, Lauren E. Sedita, et al. · Journal of Medical Economics · 1

Sa53 Impact of Eteplirsen Treatment Initiation Delays on Loss of Ambulation Incidence Among Ambulatory Patients With Duchenne Muscular Dystrophy

2026 · Lauren Sedita, Alexa Klimchak, et al. · Value in Health

Ee241 Modeling the Lifetime Benefits of Eteplirsen in Patients With Duchenne Muscular Dystrophy

2026 · Lauren Sedita, Alexa Klimchak, et al. · Value in Health

EE291 Ethical Implications of Quality-Adjusted Life Year Assessments for Patients with Disabilities: A Duchenne Muscular Dystrophy Case Study

2023 · A.C. Klimchak, L. Sedita, et al. · Value in Health

PCR23 Cataloging Health-Related Quality of Life Estimates for Duchenne Muscular Dystrophy and Related Conditions

2022 · L Do, L Sedita, et al. · Value in Health

Works count: 16

Citation count: 56

H-index: 5

I10-index: 3